Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough

Next Previous
Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Cough
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CANAL
  • Sponsors Trevi Therapeutics

Most Recent Events

  • 09 Apr 2024 According to a Trevi Therapeutics media release, data from this study will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22.
  • 30 Jun 2023 According to a Trevi Therapeutics media release, data from this trial will be presented at the American Cough Conference.
  • 24 May 2023 Results of Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic-Pulmonary-Fibrosis-related Chronic Cough, presented at the 119th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top